Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen

Technology appraisal guidance
Reference number: TA259
Published: 27 June 2012
Last updated: 27 July 2016

Information for the public

Abiraterone for metastatic prostate cancer after treatment to reduce testosterone and docetaxel chemotherapy (PDF 181 KB)

Published:

27 June 2012